Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
- Cortellini A.
- Tiseo M.
- Banna G. L.
- Cappuzzo F.
- Aerts J. G. J. V.
- Barbieri F.
- Giusti R.
- Bria E.
- Cortinovis D.
- Grossi F.
- Migliorino M. R.
- Galetta D.
- Passiglia F.
- Santini D.
- Berardi R.
- Morabito A.
- Genova C.
- Mazzoni F.
- Di Noia V.
- Signorelli D.
- Tuzi A.
- Gelibter A.
- Marchetti P.
- Macerelli M.
- Rastelli F.
- Chiari R.
- Rocco D.
- Gori S.
- De Tursi M.
- Mansueto G.
- Zoratto F.
- Santoni M.
- Tudini M.
- Rijavec E.
- Filetti M.
- Catino A.
- Pizzutilo P.
- Sala L.
- Citarella F.
- Marco R.
- Torniai M.
- Cantini L.
- Targato G.
- Sforza V.
- Nigro O.
- Ferrara M. G.
- D'Argento E.
- Buti S.
- Bordi P.
- Antonuzzo L.
- Scodes S.
- Landi L.
- Guaitoli G.
- Baldessari C.
- Della Gravara L.
- Dal Bello M. G.
- Belderbos R. A.
- Bironzo P.
- Carnio S.
- Ricciardi S.
- Grieco A.
- De Toma A.
- Proto C.
- Friedlaender A.
- Cantale O.
- Ricciuti B.
- Addeo A.
- Metro G.
- Ficorella C.
- Porzio G.
DOIAbstract
Background: Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. Methods: We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naïve NSCLC and a PD-L1 expression of ≥ 50%. Results: One thousand and twenty-six consecutive patients were included. The objective response rate (ORR) was 44.5% (95% CI 40.2–49.1), while the median progression free survival (PFS) and overall survival (OS) were 7.9 months (95% CI 6.9–9.5; 599 events) and 17.2 months (95% CI 15.3–22.3; 598 censored patients), respectively. ECOG-P...
Add to ORKG